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Little is known about the function of microRNA-224 (miR-224) in medullary thyroid cancer (MTC). This study investigated
the role of miR-224 expression in MTC and correlated it with mutation status in sporadic MTCs. A consecutive series of 134
MTCs were considered. Patients had a sporadic form in 80% of cases (107/134). In this group, REarranged during
transfection (RET) and rat sarcoma (RAS) mutation status were assessed by direct sequencing in the tumor tissues.
Quantitative real-time polymerase chain reaction was used to quantify mature hsa-miR-224 in tumor tissue. RAS (10/107
cases, 9%) and RET (39/107 cases, 36%) mutations were mutually exclusive in sporadic cases. miR-224 expression was
signiﬁcantly downregulated in patients with the following: high calcitonin levels at diagnosis (p = 0 03, r = − 0 3); advanced
stage (p = 0 001); persistent disease (p = 0 001); progressive disease (p = 0 002); and disease-related death (p = 0 0001). We
found a signiﬁcant positive correlation between miR-224 expression and somatic RAS mutations (p = 0 007). Patients
whose MTCs had a low miR-224 expression tended to have a shorter overall survival (log-rank test p = 0 005). On
multivariate analysis, miR-224 represented an independent prognostic marker. Our data indicate that miR-224 is upregulated
in RAS-mutated MTCs and in patients with a better prognosis and could represent an independent prognostic marker in
MTC patients.
1. Introduction
Medullary thyroid carcinoma (MTC) is a rare neuroendo-
crine cancer originating from parafollicular, calcitonin-
(Ct-) producing C-cells. It accounts for 5–10% of all thyroid
carcinomas with a global 10-year survival rate around 65% to
70%. About 75% of MTCs are sporadic, while the remainders
are hereditary, due to germline mutations that activate the
REarranged during transfection (RET) proto-oncogene [1].
Various clinical, pathological, and genetic variables have
been proposed as prognostic markers, including serum
calcitonin (Ct) levels at diagnosis, extent of nodal disease,
distant metastasis, pathological stage, and mutational dam-
age in tumor suppressor genes [2]. Distinctive germinal
RET mutations in the inherited forms and somatic RET
mutations in sporadic cases represent the most important
molecular markers for an adequate prognostic stratiﬁcation
of MTC patients [3–6].
It has been demonstrated that a combined analysis of
somatic RET and Ki-67 is useful for identifying patients with
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a more aggressive cancer, and their joint assessment could
ameliorate the initial risk stratiﬁcation of patients with spo-
radic MTC, and thus be of prognostic relevance [7].
Moura et al. recently reported ﬁnding RAS somatic muta-
tions in 68% of RET-negative sporadic MTCs. RASmutations
were detected only inH-RAS and K-RAS genes (not inN-RAS
genes), apparently representing an alternative genetic event
to RET mutations in sporadic MTC. These results were
reproduced by others, who found proportion RAS-mutated
cases ranging from 0% to 26.2% of MTCs. According to a
recent analysis conducted by Ciampi et al. on one of the larg-
est series in the literature [8], the average prevalence of RAS
mutations in sporadic MTC is around 8.8%, and these
authors conﬁrmed that RET and RAS mutations were mutu-
ally exclusive. On the other hand, 40–60% of sporadic MTCs
remained unassociated with any recognized genetic event.
The discovery of single strands of noncoding RNA in the
human genome and their role in modulating gene expression
at post-transcriptional level represent a great breakthrough in
the postgenome sequencing era. MicroRNAs are small and
bind to the 3′-untranslated region of target genes, suppressing
translation and/or causing mRNA degradation. That is why
microRNA can play an important part in essential processes
such as cell diﬀerentiation, growth, and cell death [9]. Inves-
tigating the role of microRNAs is an essential aspect of cancer
research [10], and there has been a growing interest of late in
how they may inﬂuence the pathogenesis and prognosis of
MTC [11–15]. In particular, the role of miR-224 in cancer
is under investigation and has yet to be clearly established.
It seems to be a negative prognostic factor in lung adenocar-
cinoma, colorectal cancers, hepatocellular carcinoma, and
cervical carcinoma [16–19]. On the other hand, several
recent studies have identiﬁed its overexpression as a marker
of a greater radio-sensitivity in glioblastoma and chemo-
sensibility in prostatic carcinoma [20, 21]. These ﬁndings
indicate that miR-224 has an indispensable role in cell prolif-
eration, but also in the apoptosis of cancer cells, and the cru-
cial balance between these two processes decides the miR-224
phenotype identiﬁable in tumor cells [22].
The aims of the present study on a large series of
familial and sporadic cases of MTC were as follows: (a)
to conﬁrm our previous ﬁndings concerning miR-224
expression and its relationship with patient outcome; (b) to
elucidate its relationship with the main molecular events
responsible for MTC.
2. Materials and Methods
2.1. Patients. The cases considered were retrospectively
selected from the electronic archives of the Surgical Pathol-
ogy and Cytopathology Unit at the University of Padua,
based on the elevated calcitonin levels and the diagnosis on
MTC. All patients involved in this study gave their written
informed consent, and the institute’s ethical regulations on
research on human tissues were followed.
The study concerned a consecutive series of 134 patients
with MTC (107 sporadic and 27 familial; 54 males and 80
females; median age 59, range 5–87 years) collected from
2006 to 2015 with a median follow-up of 40 months (range
1–140 months). Serum Ct levels at diagnosis were available
for most all the patients, who were considered biochemically
cured if they had basal Ct levels below 10pg/ml a year after
primary surgery, and/or at the latest follow-up. Disease
progression status was deﬁned based on increasing disease
burden, according to RECIST criteria, and/or on Ct/CEA-
doubling times lower than 24 months. Patients were
considered with stable disease if Ct/CEA-doubling times were
higher than 24 months, without increasing disease burden [4].
At the end of the study period, 65% of patients (86/133)
were biochemically disease-free judging from their latest Ct
test (which was unavailable for 1 patient). During the study
period, 13% of the patients (17/134) had progressive disease,
and 8 of them were treated with tyrosine kinase inhibitors
(TKI). By the end of the study period, 7% (9/132) had died
of their disease.
2.2. RET and RAS Analysis. For each cancer sample, before
DNA/RNA extraction, two experienced pathologists (F. G.
and G. P.) analyzed a frozen section slightly colored by
hematoxylin and eosin conﬁrming MTC diagnosis and
checking that at least 70% of cancer cells were present.
DNA was extracted from tissue and from whole-blood
samples using the DNeasy Blood and Tissue kit (Qiagen,
Milano, Italy) according to the manufacturer’s protocol
in order to establish their mutational status and whether
any mutations were germline or sporadic. Analyses were
run for RET (NM_020975.4) (exons 5, 8, 10, 11, 13, 14, 15,
and 16), N-RAS (NM_002524.3) (exons 2 and 3), K-RAS
(NM_033360.2) (exons 2 and 3), and H-RAS (NM_005343.2)
(exons 2 and 3) mutations by direct sequencing (bidirec-
tionally, as standard practice in positive samples), as
explained elsewhere [7, 23]. When RET or RAS mutations
were found, we conﬁrmed the results by a new ampliﬁca-
tion PCR product and then bidirectionally sequencing.
2.3. miR-224 Quantitative Real-Time Polymerase Chain
Reaction. Tissue cores were deparaﬃnized with xylene at
50°C for 3min. Total RNA extraction was done using the
RecoverAll kit (Ambion, Austin, Texas, USA) according to
the manufacturer’s instructions. The NCode™ miRNA
qRT-PCR method (Invitrogen, Carlsbad, California, USA)
was used to detect and quantify mature hsa-miR-224
(primer: 5′-gca agt cac tag tgg ttc cgt t-3′) on a real-time
LightCycler 480 instrument, according to the manufacturer’s
instructions (Roche, Milan, Italy). Normalization was per-
formed with the small nuclear RNA U6B (RNU6B; primer:
5′-acg caaattcgtgaagcg tt-3′). Data were analyzed using the
comparative cycle threshold (CT) method by LightCycler®
Relative Quantiﬁcation Software, 2001. All real-time reac-
tions, including no template controls, were run in duplicate,
as described elsewhere [24].
2.4. Statistical Analysis. All statistical analyses were per-
formed using the MedCalc software (rel. 11.6.0). The
Kolmogorov-Smirnov test was used to assess the normal dis-
tribution of each variable. After logarithmic transformation,
the t-test and ANOVA were used to measure diﬀerences in
miR-224 expression levels in diﬀerent subgroups based on
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clinical/pathological variables (female versus male, diﬀerent
stages at diagnosis, lower versus higher Ct levels at diagnosis,
biochemically cured status versus persistent disease, disease
progression versus a stable disease, and death versus alive)
and molecular features (RET/RAS status). The Mann-
Whitney test and Kruskal-Wallis test for nonparametric data
were used to correlate Ct levels with pathological and molec-
ular data and patient outcome. Fisher’s exact test was used to
study the inﬂuence of somatic mutations on patient outcome
in sporadic MTC cases. A rank correlation analysis was used
to study the inﬂuence of miR-224 on CT levels at diagnosis.
The Kaplan-Meier method was used to estimate the survival
rates, and the log-rank test was used to assess the survival
diﬀerences between the groups (the miR-224 levels were
dichotomized as “high” or “low” based on the mean value
of the variable). Multiple logistic regression was also used
to ascertain the independent eﬀect of miR-224 and the clini-
cal and pathological features considered on the outcome of
MTC patients. Diﬀerences were considered statistically sig-
niﬁcant when p was less than 0.05.
3. Results
Table 1 shows patients’ clinical and pathological ﬁndings and
their molecular RET/RAS status.
We initially examined the clinical/pathological diﬀer-
ences in relation to serum Ct levels at diagnosis, then we con-
sidered the diﬀerences in miR-224 expression level in relation
to the following: (a) clinical/pathological ﬁndings (CT level at
diagnosis, nodal and distant involvement, and TNM stage);
(b) patient’s outcome; and (c) somatic RET and RAS muta-
tions in sporadic MTCs.
As expected, higher serum Ct levels at diagnosis corre-
lated positively with the presence of nodal and distant
metastases, higher stage disease at diagnosis (for all variables,
p = 0 0001; t-test), persistent disease during the follow-up
(p = 0 0001; t-test), and a higher risk of disease-related death
(p = 0 0001; t-test).
The expression levels of miR-224 were signiﬁcantly asso-
ciated with patients’ main clinical and pathological ﬁndings
and with their outcome: there was a statistically signiﬁcant
negative association between miR-224 expression level and
serum Ct level at diagnosis: the higher the former, the lower
the latter (p = 0 03, r = − 0 3; rank correlation). We found
lower miR-224 values in patients with advanced stage disease
at diagnosis (p = 0 001; ANOVA): patients with nodal and
distant metastases at diagnosis had signiﬁcantly lower
miR-224 levels (p = 0 005 and p = 0 0001, resp.; t-test).
We also found signiﬁcantly lower miR-224 expression levels
during the study period in patients with persistent disease,
progressive disease, and fatal disease progression (p = 0 001,
p = 0 002, and p = 0 0001, resp.; t-test) (Figure 1). As
expected from the Kaplan-Meier analysis and log-rank test,
patients with a low miR-224 expression tended to have a
shorter overall survival than those with a high miR-224
expression levels (p = 0 005; log-rank test) (Figure 2).
We found somatic RETmutations in 36% of cases of spo-
radic MTC (39/107), most of them located on exon 16 at
codon 918 (M918T in 23/39; 59%). In one patient (2.6%),
RET mutation was on exon 8 (A513G), in 2 (5.1%) on exon
10 (C609S, C618R), and in 8 (20.5%) on exon 11 (2 with a
C630R, 1 with a C630S, 2 with a C634Y, 1 with a C634W, 1
with a del613E, and 1 patient with a p.L629_L633del.). Five
patients (12.8%) had their RET mutation on exon 15 (3 with
a A883F and 2 with a p.D898_E901del). Somatic RAS muta-
tions were found in 10 sporadic MTC patients (10/107; 9%):
3 had a mutation in K-RAS (two G12R and one G13R); one
had a mutation in N-RAS (Q61L); and 6 had a mutation in
H-RAS (two Q61R, one Q61K, one M72I, one G12R, and
one was a novel G60D mutation, never previously reported
in the literature). This last novel mutation warrants further
study to clarify its role and importance, and the patient car-
rying this G60D mutation was consequently excluded from
Table 1: Clinical, pathological, and molecular data on MTC cases.
MTC
Total number 134
Gender
Male 54/134 (37%)
Female 80/134 (43%)
Median age (95%CI) 58.5 (55–61)
Median follow-up in months (95%CI) 40 (32–42)
Median calcitonin level in pg/ml at
diagnosis (95%CI)
466 (5.5–22931)
Stage
I 62/134 (46%)
II 26/134 (19%)
III 13/134 (10%)
IV 33/134 (25%)
Lymph node involvement
Present 46/134 (34%)
Absent 88/134 (66%)
Distant metastases
Present 12/134 (9%)
Absent 122/134 (91%)
Germline RET mutation
Present 27/134 (20%)
Absent 107/134 (80%)
Sporadic RET mutation
Present 39/107 (36%)
Absent 68/107 (64%)
Sporadic RAS mutation
Present 10/107 (9%)
Absent 94/107 (91%)
Biochemical cure1
Present 86/133 (65%)
Absent 35/133 (35%)
Disease progression
Present 17/133 (13%)
Absent 116/133 (87%)
Disease-related death2 9/132 (7%)
1Ct level was unavailable for one patient. 2Two patients were lost to
follow-up.
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Figure 1: (a) Correlation between miR-224 expression level and persistent disease: lower levels of miR-224 were associated with higher risk of
persistent (box-and-whisker plot, p = 0 001). (b) Correlation between miR-224 expression level and disease progression: lower levels of
miR-224 were associated with higher risk of disease progression (box-and-whisker plot, p = 0 002). (c) miR-224 expression levels and
death for disease progression. At the end of the follow-up, patients who died with progressive disease had lower miR-224 levels
(box-and-whisker plot, p = 0 0001).
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the statistical analysis. Here again, we conﬁrmed that RAS
and RET sporadic mutations were mutually exclusive.
In the sporadic cases, RET somatic mutations corre-
lated with the following: the presence of nodal metastases
(p = 0 02, Fisher’s exact test); distant metastases at diagnosis
(p = 0 01, Fischer’s exact test); and advanced stage at diagno-
sis (p = 0 02; Fisher’s exact test). RET mutations also corre-
lated with persistent disease at the end of the follow-up and
an increased risk of disease-related death: the prevalence of
RET mutations was signiﬁcantly lower among patients who
were cured than among those with persistent disease at the
latest follow-up (28% versus 50%, p = 0 04; Fisher’s exact
test), while it was much higher among patients who died of
their disease than among those still alive (78% versus 32%,
p = 0 02; Fisher’s exact test). We found no signiﬁcant associ-
ation between the presence of RET mutations and miR-224
expression levels. Furthermore, when we compared MTC
outcome according to diﬀerent RETmutations (M918T cases
versus non-M918T ones), we found a signiﬁcant association
between the presence of the M918T mutation and persistent
disease (p = 0 02, by chi-squared test). No other signiﬁcant
association was found.
When we considered the associations between the
presence of RAS somatic mutations and the main clinical
and pathological variables, we found no statistically signiﬁ-
cant correlations. However, all RAS-mutated patients were
alive at the end of the study period: one had biochemical evi-
dence of disease with stably low serum Ct levels (around
45ng/L); the others were biochemically cured. We also found
a signiﬁcant positive association between RAS-mutated status
and miR-224 expression levels: the presence of RAS muta-
tions was associated with higher miR-224 levels (p = 0 007;
t-test), and the association was conﬁrmed after the exclusion
of RET-positive patients, too (p = 0 03; t-test), conﬁrming
that sporadic RAS+/RET−MTC is a less aggressive pheno-
type (Figure 3). In addition, in Table 2, we reported
clinical data based on RET+/RAS− versus RET−/RAS− versus
RET−/RAS+ to clearly highlight the diﬀerent outcomes due
to the mutational proﬁle.
Finally, our multivariate logistic regression analysis dem-
onstrated that lower serum Ct levels at diagnosis and higher
levels of miR-224 expression correlated independently with
biochemical cure (OR 0.999, 95%CI 0.9987–0.999 and OR
1.4, 95%CI 1.06–1.8, resp.). Stage at diagnosis and miR-224
expression levels correlated independently with disease pro-
gression (OR 29.8, 95%CI 3.7–243.3 and OR 0.7, 95%CI
0.5–0.9, resp.), but only miR-224 levels correlated indepen-
dently with disease-related death (OR 0.3, 95%CI 0.1–0.6).
4. Discussion
It has been estimated that more than 500 miRNAs are
expressed in humans [25]. These miRNAs are believed to
regulate the expression of nearly 5000 human genes or 30%
of all human proteins. Recent evidence has shown that the
interactions between miRNAs and their numerous mRNA
targets may have important roles in gene control inside
the cells and may be implicated in a variety of biological
processes, such as cellular diﬀerentiation, proliferation,
and apoptosis. By ﬁne-adjusting gene expression, miRNAs
may govern aspects that are crucial in determining cancer
phenotypes (i.e., signaling, diﬀerentiation, invasion, and
metastasis). They target both tumor suppressor and onco-
genic pathways [26], and their altered expression carries
great diagnostic and prognostic potential [27–29]. In addi-
tion, miRNAs are highly stable and can be detected reliably
in archival clinical samples and cytology specimens and are
therefore considered ideal candidate biomarkers [30].
miR-224 is a microRNA commonly dysregulated in most
human cancers that aﬀects crucial cellular processes and
resides in chromosome Xq28 [22]. The intriguing role of
miR-224 has yet to be fully elucidated. It may depend on
the expression of miR-224 target genes in various cell types,
since it can promote or inhibit cancer cell growth, depending
on the histotype of the malignancy concerned. Some surveys
recently suggested that miR-224 overexpression could play a
signiﬁcant part in promoting tumor cell proliferation and
migration, with an oncogenic role. Yu et al. found miR-224
upregulation and AKT activation synergistically associated
with tumor progression in hepatocellular carcinoma (HCC)
[25]. Lan et al. found that HCV-induced low autophagy
could lead to a high miR-224 expression with a tumorigenic
eﬀect [16]. Huang et al. suggested that miR-224 might have
an important role in promoting the onset and progression
of bone metastases from breast cancer [31]. miR-224 is
an independent prognostic marker in cervical cancer and
lung cancer too [17, 19, 32]. On the other hand, Mencia
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Figure 2: miR-224 and survival curve. On Kaplan-Meier analysis,
patients with lower miR-224 expression levels tended to have a
shorter survival than those with higher miR-224 levels. The
miR-224 levels were dichotomized as “high” or “low” based on the
mean value of the variable (log-rank test p = 0 005).
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et al. demonstrated that miR-224 underexpression leads to
insensitivity towards methotrexate, favoring a resistant phe-
notype [18]. In glioblastoma, miR-224 overexpression
increases radiation sensitivity, thus improving outcomes,
and patients with high miR-224 expression levels reportedly
have a better overall survival [20]. Finally, miR22-4 downreg-
ulation was found to promote tumor progression in prostate
cancer [33]. It is also worth mentioning the recent ﬁnding
that, although miR-224 upregulation is a known negative
prognostic factor in HCC, the high miR-224 phenotype in
this cancer has been found associated with a better response
to sorafenib, an inhibitor of several tyrosine kinase receptors,
such as RET, RAF kinase, and vascular endothelial growth
factor (VEGF) receptor, that is also used in MTC [34]. In
the light of the above ﬁndings, and as demonstrated for other
miRNAs, such as miR-221 and miR-222 [35-37], miR-224
seems to have a dual mode of action that depends on the type
of cancer involved: it acts as an onco-miR in some cancers
and as an oncosuppressor-miR in others, suggesting that dif-
ferent molecular targets and networks are regulated by miR-
224 in diﬀerent neoplastic scenarios. As Croce put it, “before
describing a miRNA as a tumor suppressor or an oncogene, it
is necessary to specify in which cell or tissue, as cellular con-
text is crucial for the function of miRNAs” [38].
To our knowledge, this is the ﬁrst study to explore the
expression proﬁle of miR-224 in a large cohort of MTC
patients, assessing its relationship with clinical, pathological,
and molecular features. The literature currently provides lit-
tle or no information on miR-224 expression levels in neuro-
endocrine tumors. A previous study of ours on a small series
of 34 MTC patients found that miR-224 could represent a
prognostic biomarker associated with a better outcome
[11]. Our present ﬁndings conﬁrmed as much, since miR-
224 expression levels were signiﬁcantly lower in patients with
distant metastases, persistent disease, and disease progres-
sion during their follow-up. More importantly, as already
shown in glioblastoma tissues, we ascertained that miR-224
expression levels was signiﬁcantly associated with patient
survival. Our Kaplan-Meier analysis showed that patients
with tumors showing a low miR-224 expression levels were
likely to have a signiﬁcantly shorter overall survival than
those with a high miR-224 expression levels, strongly sug-
gesting that low miR-224 expression levels is a marker of a
poor prognosis in patients with MTC. In association with
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Figure 3: Correlation between miR-224 expression level and mutational status. The presence of a RAS mutation was associated with higher
levels of miR-224 (box-and-whisker plot, p = 0 03).
Table 2: Clinical data based on RET and RAS mutational status in sporadic MTCs.
RET+/RAS−
n = 39
(%)
RET−/RAS−
n = 58
(%)
RAS+/RET−
n = 91
(%)
p
Median calcitonin level in pg/ml at diagnosis (n = 106) 700 (83–22931) 331 (20–42300) 402 (61–747) 0.01
Stage
I-II (n = 66) 18 (46%) 41 (71%) 7 (78%)
0.03
III-IV (n = 40) 21 (54%) 17 (29%) 2 (22%)
Lymph node metastases (n = 40) 21 (54%) 17 (29%) 2 (22%) 0.03
Biochemical cure2 (n = 64) 18 (46%) 38 (67%) 8 (89%) 0.03
Disease progression (n = 15) 9 (24%) 6 (10%) 0 0.08
Disease-related death3 (n = 9) 7 (18%) 2 (4%) 0 0.03
1One patient with a novel RAS mutation was excluded from statistical analysis. 2Ct level was unavailable for one patient. 3Two patients were lost to follow-up.
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serum Ct levels at diagnosis and stage of disease, miR-224
emerged from our multivariate analysis as an independent
prognostic marker.
Our ﬁndings also support the positive prognostic role of
RAS mutation found in a previous multicenter study [8]: all
of our RAS-mutated patients were alive, and they had a less
aggressive MTC phenotype and higher levels of miR-224
expression (although, based on our data, we cannot rule out
the possibility of such associations being accidental). Finally,
in line with other reports, we found that RET and RASmuta-
tions were mutually exclusive [39–42].
RET activation stimulates multiple downstream path-
ways, promoting cell growth, proliferation, survival, and dif-
ferentiation [43]. Two of the main pathways involved are the
mitogen-activated protein kinase (MAPK) and the phosphoi-
nositide 3-kinase (PI3K)/AKT pathways [43]. It remains to
be seen whether RAS mutations can also lead to the activa-
tion of both of these signaling pathways in sporadic MTC,
or whether there is a preferential activation pathway. Lyra
et al. examined mTOR activation in a series of 87 MTCs
(10 familial and 77 sporadic) and found RAS mutations sig-
niﬁcantly associated with a more intense expression of
phospho-S6 ribosomal protein (p-S6, a downstream eﬀector
of mTOR) [44], pointing to an association between mTOR
pathway activation and the presence of RAS mutations in
MTC. We consequently conducted a recent study and
demonstrated that MTC-harboring RAS mutations showed
a preferential activation of the PI3K/Akt/mTOR pathway,
revealed by an intense phospho-Akt reactivity pattern on
Western blot analysis [24]. The diﬀerent outcomes in RAS-
versus RET-mutated patients could be due to these diﬀerent
activation pathways. The present study showed that, together
with the presence of RAS mutations, higher miR-224 expres-
sion levels are also molecular markers of a favorable progno-
sis in sporadic MTC. Further studies are now needed to
clarify whether these two factors are both implicated in the
same signaling network.
In the clinical setting, Ct-doubling time and CEA-
doubling time represent the most important markers for pre-
dicting the behavior of MTC [4], but these parameters
change over time, being longer when the disease is in its early
stages and shorter in later stages, when there is disease pro-
gression [8]. The molecular characterization of sporadic
MTC at diagnosis, based on a search for somatic HRAS,
KRAS, NRAS, or RET mutations, or miRNA expression pro-
ﬁling, will hopefully pave the way to a customized patient
follow-up from the outset in the near future [3, 8]. In addi-
tion, the discovery of miRNAs oﬀers a novel mechanism
for diﬀerent treatment options and eﬀorts to develop new
modulators capable of inhibiting oncogenic miRNAs by
using miRNA antagonists (anti-miRs), or by introducing a
tumor suppressor miRNA mimetic to restore a loss of func-
tion [45–47]. Judging from our data, miR-224 acts as an
oncosuppressor-miR in MTC and lower miR-224 expression
levels serves as an independent prognostic molecular marker
of a more aggressive disease that can identify patients at risk
of progression andMTC-related death. Thanks to its stability
and the reliability with which it can be assayed in diﬀerent
types of specimen (plasma, cytology, and frozen tissue),
miR-224 could represent an ideal marker in MTC, enabling
an improvement in patients’ risk stratiﬁcation from the start.
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